Zelavespib (PU-H71)

別名：NSC 750424

製品コード：S8039 純度：99.01%

Zelavespib (PU-H71, NSC 750424) is a potent and selective inhibitor of HSP90 with IC50 of 51 nM. Phase 1.

CAS No. 873436-91-0

サイズ	価格(税別)	在庫状況
10mM (1mL in DMSO)	JPY 29500	国内在庫なし(納期7~10日)
10mg	JPY 22000	国内在庫あり
25mg	JPY 37000	国内在庫あり
100mg	JPY 101800	国内在庫なし(納期7~10日)
1g	JPY 448500	国内在庫なし(納期7~10日)

代表番号: 045-509-1970\|電子メール：[email protected] よく尋ねられる質問

文献中Selleckの製品使用例（13）

カスタマーフィードバック1例

製品安全説明書

現在のバッチを見る：純度： 99.01%

99.01

Zelavespib (PU-H71)関連製品

関連ターゲット	HSP40 HSP70 HSP90 HSP105 HSF1	もっと見る
関連製品	Tanespimycin (17-AAG) Luminespib (NVP-AUY922) Elesclomol (STA-4783) Ganetespib (STA-9090) Alvespimycin (17-DMAG) HCl VER155008 BIIB021 Onalespib (AT13387) NVP-BEP800 KRIBB11 SNX-2112 HA15 HSP990 (NVP-HSP990) NMS-E973 Apoptozole XL888 PF-04929113 (SNX-5422) KNK437 Teprenone TRC051384 VER-50589 Rocaglamide VER-49009 Pimitespib (TAS-116) JG98 DTHIB KW-2478	もっと見る
関連化合物ライブラリー	Kinase Inhibitor Library Angiogenesis Related compound Library TGF-beta/Smad compound library Cytoskeletal Signaling Pathway Compound Library Anti-Cardiovascular Disease Compound Library	もっと見る

シグナル伝達経路

HSP (HSP90)シグナル伝達経路

HSP (HSP90)阻害剤の選択性比較

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	活性情報	PMID
NCI-H526 cells	Function assay	1 μM	24 h	Binding affinity to HSP90 in human NCI-H526 cells at 1 uM after 24 hrs by fluorescence polarization assay	17603540
MCF7 cells	Function assay		24 h	Inhibition of Hsp90 in human MCF7 cells assessed as Her2 level after 24 hrs by Western blot, IC50=0.06 μM	18571929
NCI-H1299 cells	Function assay		12 h	Reduction in oxygen consumption rate in human NCI-H1299 cells incubated for 12 hrs	25383915
NCI-H69 cells	Function assay		24 h	Binding affinity to HSP90 in human NCI-H69 cells after 24 hrs by fluorescence polarization assay	17603540
NCI-N417 cells	Function assay		24 h	Binding affinity to HSP90 in human NCI-N417 cells after 24 hrs by fluorescence polarization assay	17603540
NCI-H187 cells	Function assay		24 h	Binding affinity to HSP90 in human NCI-H187 cells after 24 hrs by fluorescence polarization assay	17603540
NCI-H510 cells	Function assay		24 h	Binding affinity to HSP90 in human NCI-H510 cells after 24 hrs by fluorescence polarization assay	17603540
SKBR3 cells	Function assay		24 h	Binding affinity to HSP90 in human SKBR3 cells after 24 hrs by fluorescence polarization assay	17603540
H69AR cells	Function assay		96 h	Inhibition of HSP90-mediated antiapoptotic activity in human H69AR cells assessed as induction of cell growth arrest at 10 after 96 hrs by propidium iodide staining-based flow cytometry	17603540
NCI-H526 cells	Function assay		24 h	Binding affinity to HSP90 in human NCI-H526 cells after 24 hrs by fluorescence polarization assay	17603540
MDA-MB-468 cells	Function assay			Inhibitory activity against Hsp90 in human breast cancer MDA-MB-468 cell line, EC50=0.0102 μM	16392823
SKBr3 cells	Growth inhibition assay			Growth inhibition in human breast cancer SKBr3 cell line using SRB, IC50=0.05 μM	16392823
MRC5 cells	Cytotoxicity assay			Cytotoxicity against normal lung fibroblast MRC5 cell line, IC50=1 μM	16392823
他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

生物活性

製品説明

Zelavespib (PU-H71, NSC 750424) is a potent and selective inhibitor of HSP90 with IC50 of 51 nM. Phase 1.

特性

Purine-based, HSP90-selective inhibitor.

Targets

HSP90 ^[1]

51 nM

In Vitro
In vitro	PU-H71 (1 μM) potently suppresses the growth of triple-negative breast cancers (TNBC) cell lines MDA-MB-468, MDA-MB-231, and HCC-1806 with IC50 of 65, 140 and 87 nM, respectively. PU-H71 (1 μM) kills 80%, 65%, and 80% of the initial population of MDA-MB-468, MDA-MB-231, and HCC-1806 cells, respectively. PU-H71 (0.25-1 μM) induces a dose-dependent degradation or inactivation of tumor driving molecules, including EGFR, IGF1R, HER3, c-Kit, Raf-1and Akt. Treatment for 24 h with 1 μM PU-H71, augments the percent of cells in G2-M phase of MDA-MB-468 to 69%, mediated by reduction in CDK1 and Chk1 expression. PU-H71 induces apoptosis in TNBC in part by inactivation and downregulation of Akt and Bcl-xL. PU-H71 leads to a proteasome-mediated reduction in IRAK-1 and TBK1 levels, resulting in approximately 84% and 90% reduction in NF-κB activity in MDA-MB-231 cells treated with 0.5 and 1μM PU-H71, respectively. PU-H71 markedly contains MDA-MB-231 cell invasion, with 90% suppression at 1 μM. ^[1] PU-H71 (2.5 μM) generates endoplasmic reticulum (ER) stress and activated the Unfolded Protein Response (UPR) as evidenced by XBP1 mRNA splicing (2.3-fold) and up-regulation of Grp94 (3.7-fold), Grp78 (4.9-fold), and CHOP (48-fold) protein expression and ATF4 (1.8-fold) mRNA expression. PU-H71 (1 μM) induces the mitochondrial pathway of apoptosis in HeLa cells, mediated by caspase but not calpain activation. In response to PU-H71-induced ER stress, apoptosis is triggered in melanoma, cervix, colon, liver and lung cancer cells, but not in normal human fibroblasts. PU-H71 is able to induce apoptosis overcoming the resistance conferred by Bcl-2. ^[2] PU-H71 (30 n M) significantly reduces NOS2 activity (60% reduction) and expression in LI (1 μg/mL LPS and 5 ng/mL IFN γ)-stimulated astrocytes via inhibiting NF-κB element activation. PU-H71 displays similar effects on microglial cells as on astrocytes, with 50 nM PU-H71 needed to significantly reduce the LPS dependent nitrite release. ^[3]
Kinase Assay	HSP90 binding assay
Kinase Assay	Measurements are performed in black 96-well microtiter plates. Cell lysates are prepared by rupturing cellular membranes by freezing at -70℃ and dissolving the cellular extract in HFB [20 mM Hepes (K), pH 7.3, 50 mM KCl, 5 mM MgCl2, 20 mM Na2MoO4, 0.01% Nonidet P-40] with added protease and phosphatase inhibitors. Saturation curves are recorded in which fluorescently labeled geldanamycin (Cy3B-GM) (3 nM) is treated with increasing amounts of cellular lysates. The amount of lysate that results in polarization (mP) readings corresponding to 90%-99% bound ligand is chosen for the competition study. Here, each 96-well plate contains 3 nM Cy3B-GM, cellular lysate (amounts as determined and normalized to total Hsp90 as determined by Western blot analysis using Hsp90 purified from HeLa cells as standard) and tested Hsp90 inhibitor in a final volume of 100 μL. The plate is left for 24 h on a shaker at 4 ℃, and the fluorescence polarization (FP) values in mP are recorded. EC50 values are determined as the competitor concentrations at which 50% of the Cy3B-GM is displaced. FP measurements are performed on an Analyst GT microplate reader.
細胞実験	細胞株	Human triple-negative breast cancers cell line MDA-MB-231
	濃度	~5μM
	反応時間	3 days
	実験の流れ	Exponentially growing MDA-MB-231 cells are seeded into black 96-well microtiter plates and incubated in medium containing either vehicle control (DMSO) or compounds for the indicated time at 37 ℃. Plates containing 3 replicate wells per assay condition are seeded at a density of 8×10³ cells for each cell line in 100μL medium. After exposure of cells to the Hsp90 inhibitors, plates are equilibrated to room temperature (20-25 ℃) for approximately 30 min, and 100 μL CellTiter-Glo reagent are added to each well. Plates are mixed for 2 min on an orbital shaker and then incubated for 15 min to 2 h at room temperature. The luminescence signal in each well is measured in an Analyst GT microplate reader.
実験結果図	Methods	Biomarkers	結果図	PMID
	Western blot	AKT / c-Myc / pERK / RAF1 / EWS-FLI1 / IGF-1R / PDGFRA / c-KIT / SRC EGFR / HER3 / IGF-1R / c-Kit / Raf-1 / Akt / p90RSK / CSK / Hsp70 / Hsp90 Bcl-xl / p-PDK1 / p-AKT / cPARP LYN / SYK / BTK / AKT / MEK / ERK		24388362
	Growth inhibition assay	Cell viability		19416831

In Vivo
In Vivo	PU-H71 administered at 75 mg/kg a.d. in the MDA-MB-231 model, induces a 100% complete response, and tumors are reduced to scar tissue after 37 days of treatment, accompanied with reduction in many proliferative and anti-apoptotic molecules, namely an 80%, 95%, 99%, 80%, and 65% decrease in EGFR, HER3, Raf-1, Akt, and p-Akt, respectively. PU-H71 (75 mg/kg, 3 times per week) induces a 96% inhibition of tumor growth, accompanied by an 60% reduction in tumor cell proliferation, an 85% decline in activated Akt associated with survival and high invasive potential, and a 6-fold increase in apoptosis. ^[1]
動物実験	動物モデル	Human triple-negative breast cancers xenografts MDA-MB-231
	投与量	75 mg/kg
	投与経路	i.p. on an alternate day schedule

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
臨床試験 (data from https://clinicaltrials.gov, updated on 2024-05-22)
NCT05612633	Withdrawn	Accelerated Phase MPN\|Blast Phase MPN	Samus Therapeutics Inc.	June 15 2022	Phase 2
NCT03935555	Terminated	Primary Myelofibrosis (PMF)\|Post-Polycythemia Vera Myelofibrosis (Post-PV MF)\|Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF)	Samus Therapeutics Inc.	August 12 2019	Phase 1
NCT03373877	Terminated	Myelofibrosis\|Primary Myelofibrosis\|Post-polycythemia Vera Myelofibrosis\|Post-essential Thrombocythemia Myelofibrosis	Samus Therapeutics Inc.	May 24 2018	Phase 1
NCT01393509	Completed	Metastatic Solid Tumor\|Lymphoma\|Myeloproliferative Neoplasms (MPN)	Memorial Sloan Kettering Cancer Center	July 6 2011	Phase 1
NCT01581541	Terminated	Solid Tumors\|Lymphoma	National Cancer Institute (NCI)\|National Institutes of Health Clinical Center (CC)	April 26 2011	Phase 1

参考
[1] Caldas-Lopes E, et al. Proc Natl Acad Sci U S A, 2009, 106(20), 8368-8373. [2] Gallerne C, et al. Biochim Biophys Acta, 2013, 1833(6), 1356-1366. [3] Lisi L, et al. J Neuroimmunol, 2013, 255(1-2), 1-7.

参考

化学情報

分子量	512.37	化学式	C₁₈ H₂₁ I N₆ O₂ S
CAS No.	873436-91-0	SDF	--
Smiles	CC(C)NCCCN1C2=NC=NC(=C2N=C1SC3=C(C=C4C(=C3)OCO4)I)N
保管	3年-20°C粉	溶液の保管冷凍と解凍の繰り返しを避けるため小分けにしてください	1年-80°Cin solvent
保管	3年-20°C粉	溶液の保管冷凍と解凍の繰り返しを避けるため小分けにしてください	１ケ月-20°Cin solvent

In vitro
Batch:

DMSO : 100 mg/mL ( (195.17 mM)；吸湿したDMSOは溶解度を減少させます。新しいDMSOをご使用ください。)

Water : 100 mg/mL

Ethanol : 100 mg/mL

モル濃度計算器

in vivo
Batch:

Add solvents to the product individually and in order.

投与溶液組成計算機

実験計算

モル濃度計算器

質量	濃度	体積	分子量
=	×	×

希釈計算器分子量計算器

投与溶液組成計算機(クリア溶液)

ステップ１：実験データを入力してください。（実験操作によるロスを考慮し、動物数を1匹分多くして計算・調製することを推奨します）

投与量 mg/kg 動物平均体重 g 投与体積（動物毎）μL 動物数匹

ステップ２：投与溶媒の組成を入力してください。（ロット毎に適した溶解組成が異なる場合があります。詳細については弊社までお問い合わせください）

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

計算結果：

投与溶媒濃度： mg/ml;

DMSOストック溶液調製方法： mg 試薬を μL DMSOに溶解する（濃度 mg/mL, 注：濃度が当該ロットのDMSO溶解度を超える場合はご連絡ください。 )

投与溶媒調製方法：Take μL DMSOストック溶液に μL PEG300，を加え、完全溶解後μL Tween 80，を加えて完全溶解させた後 μL ddH₂O，を加え完全に溶解させます。

投与溶媒調製方法：μL DMSOストック溶液に μL Corn oil，を加え、完全溶解。

注意：１.ストック溶液に沈殿、混濁などがないことをご確認ください；
２.順番通りに溶剤を加えてください。次のステップに進む前に溶液に沈殿、混濁などがないことを確認してから加えてください。ボルテックス、ソニケーション、水浴加熱など物理的な方法で溶解を早めることは可能です。

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

* 必須

* 大学・企業名 大学・企業名を記入してください

* 名前 名前を記入してください

* 電子メール 電子メール・アドレスを記入してください 有効なメールアドレスを入力してください

電話番号

* 内容 お問い合わせ内容をご入力ください

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):